Suzhou Zelgen Biopharmaceuticals Co., Ltd. announced earnings results for the half year ended June 30, 2021. For the half year, the company announced sales was CNY 42.409 million. Operating loss was CNY 187.408 million. Net loss was CNY 176.970 million. Basic loss per share from continuing operations was CNY 0.74.